Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1992-06-01
1994-03-29
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514423, 514460, 514510, A61K 31675, A61K 3140, A61K 3135, A61K 3121
Patent
active
052984974
ABSTRACT:
A method is provided for preventing or reducing the risk of hypertension in normotensive patients having insulin resistance by administering a cholesterol lowering drug, such as pravastatin, alone or in combination with an ACE inhibitor, especially one containing a mercapto moiety, such as captopril or zofenopril.
REFERENCES:
patent: 4871721 (1989-06-01), Biller
patent: 4924024 (1990-05-01), Biller
Rett et al., Postgrad. Med. J. (U.K.) 1986 62/Supp. 1 pp. 59-64.
Overturf et al., Athers Sclerosis 59:283-299, 1986.
Olefsky et al, "Insulin Action and Resistance in obesity and non-insulin dependent type II diabetes mellitus," Am. J. Physiol. 1982; 243:E15-330.
Stout, R. W., "Insulin and atheroma-an update," Lancet 1987, I:1077-1079.
Ferrannini et al, "Insulin resistance in essential hypertension," N. engl. J. Med. 1987, 217:350-357.
Modan et al, "Hyperinsulinemia-alink between glucose intolerance, obesity, hypertension, dyslipoproteinaemia, elevated serum uric acid and internal kation imbalance," Diab. Met. 1987, 13:375-380.
Skarfors et al, "Do antihypertensive drugs precipitate diabetes in predisposed man?" Br. Med. J. 1989, 298:1147-1152.
Pollare et al, "Insulin Resistance is a Characteristic Feature of Primary Hypertension Independent of Obesity," Metabolism, vol. 39, No. 2 (Feb.), 1990, pp. 167-174.
Pollare et al, "A comparison of the effects of Hydrochlorothiazide and Captopril on glucose and Lipid metabolism in Patients with Hypertension," New England Journal of Medicine, 321:868-873 Sep. 28, 1989.
Rett et al, "Angiotensin converting enzyme inhibitors in diabetes: Experimental and human experience," Postgrad. Med. J. (U.K.), 1986 62/Suppl. 1 (59-64).
Jauch et al, "Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus," Eur. J. Clin. Invest. (U.K.), 1987, 17/5 (448-454).
Edelman et al, "Hyperkalemia During Treatment with HMG CoA Reductase Inhibitor," N. Engl. J. Med. (320, No. 18, 1219-20, 1989).
Zorn et al, "Prevention of Arteriosclerotic Lesions with Calcium Antagonists or Captopril in Different Rat Hypertension Models," J. Cardiovasc. Pharmacol. vol. 12 (Suppl. 6), 1988.
Someya et al, "Suppressive Effect of Captopril on Platelet Aggregation in Essential Hypertension," J. Cardiovasc. Pharmacol. 6:840-843, 1984.
Mizuno et al, "The effects of the angiotensin I-converting enzyme inhibitor, captopril, on serum lipoperoxides level and the renin-angiotensin-aldosterone and kallikrein-kinin systems in hypertensive patients," Nippon Naibunpi Gakkai Zasshi, Feb. 20, 1984.
Mizuno et al, "Acute effects of captopril on serum lipid peroxides level in hypertensive patients," Tohoku J. Exp. Med., May, 1984, 143(1) pp. 127-128.
Beisterfer et al, "Angiotensin II Induces Hypertrophy, not Hyperplasia, of Cultured Rat Aortic Smooth Muscle Cells," Circ. Res. 62:749-756, (1988).
Overturf et al, "Hypertension and Atherosclerosis in Cholesterol-Fed Rabbits Part 1, Mild, Two-Kidney, One-Clip Goldblatt Hypertension treated with Enalapril," Atherosclerosis, 59:283-299, 1986.
Cecil, Textbook of Medicine, 16 Ed., pp. 239-241, 1983.
McClard et al, "Novel Phosphonylphosphinyl (P-C-P-C-) Analogues of Biochemically Interesting diphosphates, Syntheses and Properties of P-C-P-C- Analogues of Isopentenyl Diphosphate and Dimethylallyl Diphosphate," J.A.C.S. 1987, 109, 5544-5545.
Biller et al, "Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitors of Squalene Synthetase," Journal of Medicinal Chemistry, 1988, vol. 31, No. 10, pp. 1869-1871.
Bergey James L.
Kawano James C.
Tschollar Werner
Yonce Cary S.
E. R. Squibb & Sons Inc.
Jordan Kimberly
Rodney Burton
Waddell Frederick E.
LandOfFree
Method for preventing onset of hypertension employing a choleste does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing onset of hypertension employing a choleste, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing onset of hypertension employing a choleste will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-791912